Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Weill Medical College of Cornell University
With
This phase I/II study is a treatment program for patients with relapsed or refractory multiple myeloma. Up to 48 patients will be enrolled. Phase I will follow a 3+3 dose escalation design to find the maximum tolerated dose of romidepsin in combination with pomalidomide and dexamethasone. In Phase I, subjects will receive: * Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle * Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle * Romidepsin intravenously (9 mg/m2, 12 mg/m2, 15 mg/m2 or 18 mg/m2) on days 1 and 15 of a 28-day cycle. Phase II will expand the number of subjects in the MTD arm of the trial until 48 subjects are enrolled. In Phase II, subjects subjects will receive: * Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle * Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle * Romidepsin intravenously on days 1 and 15 of a 28-day cycle at the Maximum Tolerated Dose determined by Phase I
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
